MedTrace Logo

Nexus Evaluation Primary Trident II Uncemented Shell

NCT05366712 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2026-02-13

No results posted yet for this study

Summary

This is a prospective cohort study assessing the survival of a new acetabula component which is based on the original Trident acetabular system (cementless shell) which is used for Total Hip Arthroplasty. The manufacturer recently introduced the evolution of this product, the Trident® II acetabular shell which was launched in 2017. This implant is CE marked and is now widely available for the UK market, however has minimal clinical outcomes data to support its use. As part of a stepwise introduction of devices to orthopaedic practice. This study will report the 10 year implant survival and patient functional outcomes of this new implant.

Conditions

  • Arthritis of Hip
  • Hip Dysplasia
  • Hip Arthropathy
  • Hip Osteoarthritis

Interventions

DEVICE

Stryker Trident® II HA coated cementless acetabula component

New acetabula component.

Sponsors & Collaborators

  • University of Edinburgh

    collaborator OTHER

  • NHS Lothian

    lead OTHER_GOV

Principal Investigators

  • Paul Gaston, MBChB, FRCS · NHS Lothian

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2024-11-25
Completion
2034-11-25

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05366712 on ClinicalTrials.gov